ClinicalTrials.gg
RecruitingNCT07487896Updated Jul 16, 2026

A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy

A Phase 3 interventional study of YL201 and Paclitaxel in Advanced Esophageal Squamous Cell Carcinoma, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 81 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China — 174 open to participants now, 213 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Planned enrollment
37th of 351
440 · median 70
Started
2026
with 47 others
Phase 3
52 of 401
20 open now
Primary completion
2028-04
later than 175 of 212 live
Registered
361st of 401
by date

Among the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 37th largest by planned enrollment of the 351 interventional ones that give a count, is one of 48 that started in 2026, is one of 52 in phase 3, reaches primary completion later than 175 of the 212 other live ones, and was the 361st registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

174 of the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

168 more — sign in →

All 174 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

This is a large clinical study carried out at multiple hospitals. Participants will be randomly assigned to one of two groups: one group will receive a new medicine called YL201, and the other group will receive standard chemotherapy chosen by the doctor.

The purpose of the study is to see whether YL201 works better and is safer for people with locally advanced or metastatic esophageal squamous cell carcinoma whose first-line treatment has stopped working.

The study will also look at how YL201 is processed in the body (Pharmacokinetics), whether it triggers any immune reactions, and whether certain biological markers can help predict how well it works.

03

Conditions studied

  • Advanced Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: ≥18 years;
  2. Voluntary participation in this study with signed and good compliance.
  3. PS score: 0-1;
  4. estimated >3 months;
  5. or cytologically confirmed ESCC with unresectable locally advanced or disease
  6. Previously received one line of systemic standard therapy for unresectable locally advanced or metastatic ESCC and experienced disease progression
  7. Adequate organ function.
  8. At least one
  9. Willing to provide or archived tumor tissue.

Exclusion criteria

Exclusion Criteria:

  1. Other within 5 years prior to first dose or currently concurrent malignancies.
  2. Prior treatment-related adverse events not resolved to ≤Grade 1 per v5.0, except for alopecia (any grade), hyperpigmentation (any grade), peripheral neuropathy (≤ Grade 2), and lymphopenia (≤ Grade 3).
  3. Major surgery, significant traumatic injury within 4 weeks prior to first dose, or anticipated need for major surgery during study treatment
  4. Any arterial thromboembolic event within 6 months prior to randomization, or venous thromboembolic events of Grade ≥ 3 according to NCI CTCAE version 5.0.
  5. Known active tuberculosis (TB). Participants suspected of having active TB must undergo clinical evaluation to rule it out.
  6. History of immunodeficiency or positive test for (HIV) antibodies. Participants with known active syphilis infection are also excluded.
  7. Current active infection with virus (HBV) or virus (HCV).
  8. Known allergy to any component of the product; history of severe allergic reactions (e.g., anaphylactic shock); or known history of severe reactions to other monoclonal antibodies or recombinant proteins, or previous severe infusion reactions.
  9. Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study period.
  10. Any disease, medical condition, organ dysfunction, or social/psychological circumstance that, in the investigator's judgment, may interfere with the participant's ability to sign the form (ICF), compromise cooperation or compliance with study procedures, or affect the interpretation of study results. This includes, but is not limited to, psychiatric disorders, substance/alcohol abuse, or a history of drug abuse.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
440 participants (estimated)

Study arms

  • Experimental
    YL201

    YL201 monotherapy

    Drug: YL201

  • Active comparator
    Control

    Investigator's choice of Chemotherapy

    Drug: Paclitaxel · Drug: Docetaxel · Drug: Irinotecan

Interventions

  • DrugYL201

    YL201, a B7H3 targeting ADC,administered on Day 1 of each cycle, intravenous infusion, every 3 weeks (Q3W).

  • 175 mg/m², administered on Day 1 of each cycle, intravenous infusion, every 3 weeks (Q3W).

  • 75 mg/m², administered on Day 1 of each cycle, intravenous infusion, every 3 weeks (Q3W).

  • 125 mg/m², administered on Days 1 and 8 of each cycle, intravenous infusion, every 3 weeks (Q3W).

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to the event of death from any cause.

    Time frame: Up to Approximately 36 Months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by investigator or death from any cause, whichever occurs earlier.

    Time frame: Up to Approximately 36 Months

  2. Overall response rate (ORR)

    ORR is defined as the proportion of participants achieving a best overall response of confirmed Complete response (CR) or confirmed partial response (PR) as determined by investigator based on RECIST version 1.1.

    Time frame: Up to Approximately 36 Months

  3. Disease control rate (DCR)

    DCR is defined as the proportion of participants with complete response (CR), partial response (PR), or disease stabilization (SD) as determined by the investigator according to RECIST 1.1.

    Time frame: Up to Approximately 36 Months

  4. Duration of Response (DOR)

    DOR is defined as the time interval from the date of first documentation of objective response (CR or PR) to date of the first documentation of disease progression as determined by the investigator according to RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to Approximately 36 Months

  5. Adverse Event (AE)

    The incidence and severity of adverse events, with severity graded according to the NCI CTCAE v5.0 scale.

    Time frame: Up to Approximately 36 Months

07

Study locations

80 of 81 sites recruiting
  • 144
    Anqing, Anhui, China
    Recruiting
    • study coordinator · Contact
  • 135
    Bengbu, Anhui, China
    Recruiting
    • study coordinator · Contact
  • 133
    Hefei, Anhui, China
    Recruiting
    • study coordinator · Contact
  • 143
    Hefei, Anhui, China
    Recruiting
    • study coordinator · Contact
  • 129
    Beijing, Beijing Municipality, China
    Recruiting
    • study coordinator · Contact
  • 161
    Beijing, Beijing Municipality, China
    Recruiting
    • study coordinator · Contact
  • 183
    Beijing, Beijing Municipality, China
    Recruiting
    • study coordinator · Contact
  • 119
    Chongqing, Chongqing Municipality, China
    Recruiting
    • study coordinator · Contact
  • 120
    Chongqing, Chongqing Municipality, China
    Recruiting
    • study coordinator · Contact
  • 110
    Fuzhou, Fujian, China
    Not yet recruiting
    • study coordinator · Contact
  • 147
    Fuzhou, Fujian, China
    Recruiting
    • study coordinator · Contact
  • 145
    Xiamen, Fujian, China
    Recruiting
    • study coordinator · Contact
  • 175
    Lanzhou, Gansu, China
    Recruiting
    • study coordinator · Contact
  • 149
    Guangzhou, Guangdong, China
    Recruiting
    • study coordinator · Contact
  • 154
    Guangzhou, Guangdong, China
    Recruiting
    • study coordinator · Contact
  • 112
    Nanning, Guangxi, China
    Recruiting
    • study coordinator · Contact
  • 150
    Nanning, Guangxi, China
    Recruiting
    • study coordinator · Contact
  • 184
    Foshan, Guangzhou, China
    Recruiting
    • study coordinator · Contact
  • 168
    Meizhou, Guangzhou, China
    Recruiting
    • study coordinator · Contact
  • 169
    Shantou, Guangzhou, China
    Recruiting
    • study coordinator · Contact
  • 158
    Handan, Hebei, China
    Recruiting
    • study coordinator · Contact
  • 176
    Handan, Hebei, China
    Recruiting
    • study coordinator · Contact
  • 180
    Langfang, Hebei, China
    Recruiting
    • study coordinator · Contact
  • 156
    Shijiazhuang, Hebei, China
    Recruiting
    • study coordinator · Contact
  • 159
    Shijiazhuang, Hebei, China
    Recruiting
    • study coordinator · Contact
  • 122
    Harbin, Heilongjiang, China
    Recruiting
    • study coordinator · Contact
  • 170
    Harbin, Heilongjiang, China
    Recruiting
    • study coordinator · Contact
  • 102
    Anyang, Henan, China
    Recruiting
    • study coordinator · Contact
  • 105
    Luoyang, Henan, China
    Recruiting
    • study coordinator · Contact
  • 132
    Nanyang, Henan, China
    Recruiting
    • study coordinator · Contact
  • 103
    Zhengzhou, Henan, China
    Recruiting
    • study coordinator · Contact
  • 104
    Zhengzhou, Henan, China
    Recruiting
    • study coordinator · Contact
  • 142
    Zhengzhou, Henan, China
    Recruiting
    • study coordinator · Contact
  • 113
    Wuhan, Hubei, China
    Recruiting
    • study coordinator · Contact
  • 114
    Wuhan, Hubei, China
    Recruiting
    • study coordinator · Contact
  • 148
    Wuhan, Hubei, China
    Recruiting
    • study coordinator · Contact
  • 155
    Yichang, Hubei, China
    Recruiting
    • study coordinator · Contact
  • 151
    Changsha, Hunan, China
    Recruiting
    • study coordinator · Contact
  • 182
    Changsha, Hunan, China
    Recruiting
    • study coordinator · Contact
  • 165
    Huai'an, Jiangsu, China
    Recruiting
    • study coordinator · Contact
  • 107
    Nanjing, Jiangsu, China
    Recruiting
    • study coordinator · Contact
  • 177
    Nantong, Jiangsu, China
    Recruiting
    • study coordinator · Contact
  • 140
    Suzhou, Jiangsu, China
    Recruiting
    • study coordinator · Contact
  • 171
    Taizhou, Jiangsu, China
    Recruiting
    • study coordinator · Contact
  • 136
    Xuzhou, Jiangsu, China
    Recruiting
    • study coordinator · Contact
  • 117
    Nanchang, Jiangxi, China
    Recruiting
    • study coordinator · Contact
  • 121
    Nanchang, Jiangxi, China
    Recruiting
    • study coordinator · Contact
  • 125
    Changchun, Jilin, China
    Recruiting
    • study coordinator · Contact
  • 128
    Jilin City, Jilin, China
    Recruiting
    • study coordinator · Contact
  • 126
    Shenyang, Niaoning, China
    Recruiting
    • study coordinator · Contact
  • 157
    Shenyang, Niaoning, China
    Recruiting
    • study coordinator · Contact
  • 160
    Shenyang, Niaoning, China
    Recruiting
    • study coordinator · Contact
  • 163
    Yinchuan, Ningxia, China
    Recruiting
    • study coordinator · Contact
  • 101
    Jinan, Shandong 250117, China
    Recruiting
    • study coordinator · Contact
  • 139
    Jinan, Shandong, China
    Recruiting
    • study coordinator · Contact
  • 178
    Jinan, Shandong, China
    Recruiting
    • study coordinator · Contact
  • 138
    Linyi, Shandong, China
    Recruiting
    • study coordinator · Contact
  • 141
    Linyi, Shandong, China
    Recruiting
    • study coordinator · Contact
  • 137
    Qingdao, Shandong, China
    Recruiting
    • study coordinator · Contact
  • 167
    Tai’an, Shandong, China
    Recruiting
    • study coordinator · Contact
  • 166
    Tengzhou, Shandong, China
    Recruiting
    • study coordinator · Contact
  • 106
    Shanghai, Shanghai Municipality, China
    Recruiting
    • study coordinator · Contact
  • 134
    Shanghai, Shanghai Municipality, China
    Recruiting
    • study coordinator · Contact
  • 172
    Shanghai, Shanghai Municipality, China
    Recruiting
    • study coordinator · Contact
  • 173
    Shanghai, Shanghai Municipality, China
    Recruiting
    • study coordinator · Contact
  • 123
    Taiyuan, Shanxi, China
    Recruiting
    • study coordinator · Contact
  • 127
    Xi’an, Shanxi, China
    Recruiting
    • study coordinator · Contact
  • 162
    Xi’an, Shanxi, China
    Recruiting
    • study coordinator · Contact
  • 111
    Chengdu, Sichuan, China
    Recruiting
    • study coordinator · Contact
  • 116
    Chengdu, Sichuan, China
    Recruiting
    • study coordinator · Contact
  • 118
    Chengdu, Sichuan, China
    Recruiting
    • study coordinator · Contact
  • 153
    Mianyang, Sichuan, China
    Recruiting
    • study coordinator · Contact
  • 152
    Nanchong, Sichuan, China
    Recruiting
    • study coordinator · Contact
  • 146
    Suining, Sichuan, China
    Recruiting
    • study coordinator · Contact
  • 124
    Tianjin, Tianjin Municipality, China
    Recruiting
    • study coordinator · Contact
  • 130
    Ürümqi, Xinjiang, China
    Recruiting
    • study coordinator · Contact
  • 115
    Kunming, Yunnan, China
    Recruiting
    • study coordinator · Contact
  • 108
    Hangzhou, Zhejiang, China
    Recruiting
    • study coordinator · Contact
  • 109
    Hangzhou, Zhejiang, China
    Recruiting
    • study coordinator · Contact
  • 174
    Hangzhou, Zhejiang, China
    Recruiting
    • study coordinator · Contact
  • 179
    Wenzhou, Zhejiang, China
    Recruiting
    • study coordinator · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2028, 25 months after the start.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 23, 2026
StartActual
Mar 24, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07487896
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Mar 24, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 16, 2026

Study contacts

Medilink Study Team
Contact
clinicaltrials@medilinkthera.com
051262858368

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tambotatug pelitecan

Start the discussion